Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add filters

Database
Language
Document Type
Year range
1.
J Korean Med Sci ; 36(4): e28, 2021 Jan 25.
Article in English | MEDLINE | ID: covidwho-1048950

ABSTRACT

Hospitalized coronavirus disease 2019 (COVID-19)-infected patients suffer from both physical impairments and mental stress. Respiratory insufficiency and cardiovascular disturbances require most of the intensive care interventions, but they are also accompanied by depressive conditions, sadness and fear of dying. Sedatives are mostly respiratory and cardiovascular depressants and do not provide resistance to the pro-inflammatory burst induced by the virus. Ketamine is a unique and safe drug that enables well-controlled sedation and anesthesia, attenuates depression and mitigates suicidal thoughts, without depressing respiratory or cardiovascular mechanics. This brief communication highlights the benefits potentially provided by ketamine to patients hospitalized for COVID-19 infection.


Subject(s)
COVID-19/drug therapy , COVID-19/psychology , Depression/drug therapy , Ketamine/therapeutic use , Stress, Psychological/drug therapy , Anesthesia , Anxiety/drug therapy , Critical Care , Depression/complications , Hemodynamics , Hospitalization , Humans , Hypnotics and Sedatives , Immune System , Respiratory Insufficiency , Stress, Psychological/complications , Suicidal Ideation , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL